Abramson, Vandana G. http://orcid.org/0000-0002-6855-1322
Oliveira, Mafalda
Cervantes, Andrés
Wildiers, Hans
Patel, Manish R.
Bauer, Todd M.
Bedard, Philippe L. http://orcid.org/0000-0002-6771-2999
Becerra, Carlos
Richey, Stephen
Wei, Michael C.
Reyner, Eric
Bond, John
Cui, Na
Wilson, Timothy R.
Moore, Heather M.
Saura, Cristina
Krop, Ian E.
Funding for this research was provided by:
F. Hoffmann-La Roche
Genentech
Article History
Received: 9 July 2019
Accepted: 12 July 2019
First Online: 31 July 2019
Compliance with ethical standards
:
: VGA has received research funding from Genentech, Astellas, and Lilly, and has consulted for Eisai and Novartis. MO has received remuneration from Roche, consulting or advisory fees from Roche, GSK, PUMA Biotechnology, and funding from AstraZeneca, Philips Healthcare, Genentech, Roche, Novartis, Immunomedics, Seattle Genetics, GSK, Boehringer-Ingelheim, PUMA Biotechnology (all to the Institution). AC has received consulting or advisory fees from Merck Serono, Roche, Beigene, Bayer, Servier, Lilly, Novartis, Takeda and Astelas, and funding from Genentech, Merck Serono, Roche, Beigene, Bayer, Servier, Lilly, Novartis, Takeda, Astelas, Fibrogen, Amcure, Sierra Oncology, Astra Zeneca, Medimmune, BMS, and MSD. HW has received travel support from Roche, TRM Oncology, Puma Biotechnology, and Pfizer (outside of the submitted work), and his institution has received consulting fees and honoraria from Roche, AstraZeneca, Amgen, Lilly, Novartis, AbbVie, Vifor Pharma, Pfizer, Celldex Therapeutics, Janssen-Cilag, TRM Oncology, Puma Biotechnology, Orion Corporation, and an unrestricted research grant from Roche (outside of the submitted work). MRP has received consulting or advisory fees from Exelixis, Pfizer, EMD Serono, Pharmacyclics, Genentech, and Celgene. TMB has received remuneration for employment Tennessee Oncology, remuneration for speakers’ bureau from Bayer (personal), remuneration for travel from Astellas Pharma, AstraZeneca, Celgene, Clovis Oncology, EMD Serono, Genentech, Lilly, Merck, Novartis, Ignyta, Pharmacyclics, Loxo, Bayer, Guardant Health, Moderna Therapeutics and Sysmex, consulting or advisory fees from Guardant Health (personal), Loxo (personal), Pfizer (personal), Leap Therapeutics (institutional), Ignyta (Institutional), Moderna Therapeutics (Institutional), Bayer (personal), Guardant Health and Pfizer (personal and Institutional), and Institutional funding from: Daiichi Sankyo, Medpacto, Inc., Incyte, Mirati Therapeutics, MedImmune, Abbvie, AstraZeneca, Leap Therapeutics, MabVax, Stemline Therapeutics, Merck, Lilly, GlaxoSmithKline, Novartis, Pfizer, Genentech/Roche, Deciphera, Merrimack, Immunogen, Millennium, Ignyta, Calithera Biosciences, Kolltan Pharmaceuticals, Principa Biopharma, Peleton, Immunocore, Aileron Therapeutics, Bristol-Myers Squibb, Amgen, Moderna Therapeutics, Sanofi, Boehringer Ingelheim, Astellas Pharma, Five Prime Therapeutics, Jacobio, Top Alliance BioScience, Loxo, Janssen, Clovis Oncology, Takeda, Karyopharm Therapeutics, Onyx, Phosplatin Therapeutics, Foundation Medicine and ARMO BioSciences and Bayer. PLB reports institutional grants from Bristol-Myers Squibb, Sanofi, AstraZeneca, Genentech/Roche, Servier, Merck, Nektar, Mersana, Novartis, GlaxoSmithKline, SignalChem, PTC Therapeutics (all during the conduct of the study), and is the current Chair of the Investigational New Drug Committee, Canadian Clinical Trials Group, an Executive Board Member for the Breast International Group, a Steering Committee Member for the American Association for Cancer Research Project GENIE, and a member of the NCI-BIO Breast Cancer Immunotherapy Task Force. CB has received honoraria from Taiho Pharmaceutical, consulting or advisory fees from SOBI, Ipsen, Takeda, Bayer, HERON, and Agenus, and fees from speakers’ bureau from Taiho Pharmaceutical, Bristol-Myers Squibb, and Celgene. SR has received remuneration from AstraZeneca, Genentech Inc., Genzyme Corporation, consulting or advisory fees from AstraZeneca, and funding from Acerta Pharma LLC, Eisai Inc., Eli Lilly and Company, EMD Serono, Inc., E.R. Squibb & Sons, L.L.C., Genentech, Inc., Ipsen Biopharmaceuticals, Inc., Janssen Research & Development, LLC., Janssen Research & Development, LLC., Novartis Pharmaceuticals Corporation, Tesaro, Inc. MCW, ER, JB, NC, TRW, and HMM are employees of Genentech and hold stock in Roche. CS has received travel grants from Puma Biotechnology, Pfizer, Roche, Astra Zeneca, Celgene, Daiichi Sankyo, Eisai, Genomyc Health, Novartis, Pierre Fabre, and Synthon Biopharmaceuticals, consulting or advisory fees from Puma Biotechnology, Pfizer, Roche, Astra Zeneca, Celgene, Daiichi Sankyo, Eisai, Genomyc Health, Novartis, Pierre Fabre, and Synthon Biopharmaceuticals, and funding from Roche-Genentech, Macrogenics, Pfizer, Piqur Therapeutics, Puma Biotechnology, Synthon Biopharmaceuticals, and Novartis. IEK has received grants and personal fees from Genentech/Roche (during the conduct of the study), grants from Pfizer, and personal fees from Macrogenics, Amgen, Taiho, Context Therapeutics, Seattle Genetics, and Daiichi Sankyo (outside of the submitted work). All authors received support for third-party writing assistance for this manuscript from Genentech, Inc./F. Hoffmann-La Roche Ltd.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (Supplementary methods) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.